Valion Bio, Inc. current report, 15 May 2023

Abrir documento

Filing Overview

Registrant: Tivic Health Systems, Inc. The provided metadata identifies Valion Bio, Inc., but the filing names Tivic Health Systems, Inc. as the registrant. This Form 8-K was filed on May 15, 2023, under Items 2.02 and 7.01, and reports results for the first quarter ended March 31, 2023.

Business Context and Reporting Period

The filing furnishes a press release concerning the company’s first-quarter 2023 financial results. The company is incorporated in Delaware, trades under the symbol TIVC on Nasdaq, and identifies itself as an emerging growth company.

Financial Metrics

  • Revenue, net income or loss, cash flow, margins, debt, liquidity, and other financial metrics are not included in the provided filing text.
  • The referenced Exhibit 99.1 press release may contain the detailed financial results, but its substantive contents were not provided.

Material Changes Versus Prior Period

The filing text does not provide a clear comparison with the prior comparable period or quantify any changes in operating or financial performance.

Guidance, Outlook, Risks, and Unusual Items

  • No specific financial guidance or quantified outlook is included in the provided text.
  • The filing contains customary forward-looking-statement cautionary language, noting that actual results may differ materially because of known and unknown risks and uncertainties.
  • The filing does not identify a specific unusual item, contingency, financing event, or liquidity issue in the provided text.
  • The Item 7.01 information and Exhibit 99.1 are furnished, rather than filed, for purposes of Section 18 of the Exchange Act and generally are not incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  1. Verify the registrant identity, because the request metadata names Valion Bio, Inc., while the filing names Tivic Health Systems, Inc.
  2. Review Exhibit 99.1 for first-quarter revenue, operating results, cash flow, cash balance, debt, and year-over-year comparisons.
  3. Confirm whether management provided guidance, outlook, financing plans, or material risk updates in the press release.
  4. Assess the filing’s forward-looking statements together with the company’s other SEC filings and risk factors.